PBH — Prestige Consumer Healthcare Share Price
0.000.00%
Last trade - 00:00- $3.53bn
- $4.59bn
- $1.13bn
- 92
- 62
- 87
- 95
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.56 | ||
| PEG Ratio (f) | 2.49 | ||
| EPS Growth (f) | 6.67% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.1 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 14.34 | ||
| Price to Sales | 3.18 | ||
| EV to EBITDA | 12.74 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.31% | ||
| Return on Equity | 12.98% | ||
| Operating Margin | 29.58% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 963.01 | 943.37 | 1,086.81 | 1,127.72 | 1,125.36 | 1,130.93 | 1,159.87 | 2.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +32.68 | +17.31 | +18.14 | -20.52 | +28.76 | +5.99 | +7.33 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Prestige Consumer Healthcare Inc. is consumer healthcare products company. The Company is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club and e-commerce stores in North America (the United States and Canada) and in Australia and certain other international markets. It operates through two segments: North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.
Directors
- Ronald Lombardi CHM (57)
- Christine Sacco CFO (47)
- Adel Mekhail EVP (60)
- William PPool SVP (55)
- Jeffrey Zerillo SVP (60)
- John Byom IND (67)
- Celeste Clark IND (68)
- Christopher Coughlin IND (68)
- Sheila Hopkins IND (65)
- Natale Ricciardi IND (72)
- Dawn Zier IND (56)
- Last Annual
- March 31st, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- June 24th, 2004
- Public Since
- February 10th, 2005
- No. of Shareholders
- 15
- No. of Employees
- 570
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 49,557,371
- Address
- 660 White Plains Rd, TARRYTOWN, 10591-5139
- Web
- https://www.prestigebrands.com/
- Phone
- +1 9145246800
- Auditors
- PricewaterhouseCoopers LLC
Upcoming Events for PBH
Q3 2025 Prestige Consumer Healthcare Inc Earnings Release
Similar to PBH
Abbvie
New York Stock Exchange
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Cardinal Health
New York Stock Exchange
FAQ
What is the Prestige Consumer Healthcare share price?
As of Today at 22:44 UTC, shares in Prestige Consumer Healthcare are trading at $71.32. This share price information is delayed by 15 minutes.
How has the Prestige Consumer Healthcare share price performed this year?
Shares in Prestige Consumer Healthcare last closed at $71.32 and the price had moved by +20.82% over the past 365 days. In terms of relative price strength the Prestige Consumer Healthcare share price has underperformed the S&P500 Index by -9.71% over the past year.
What are the analyst and broker recommendations for Prestige Consumer Healthcare?
The overall consensus recommendation for Prestige Consumer Healthcare is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Prestige Consumer Healthcare dividend yield?
Prestige Consumer Healthcare does not currently pay a dividend.
Does Prestige Consumer Healthcare pay a dividend?
Prestige Consumer Healthcare does not currently pay a dividend.
When does Prestige Consumer Healthcare next pay dividends?
Prestige Consumer Healthcare does not currently pay a dividend.
How do I buy Prestige Consumer Healthcare shares?
To buy shares in Prestige Consumer Healthcare you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Prestige Consumer Healthcare?
As of the previous close price of $71.32, shares in Prestige Consumer Healthcare had a market capitalisation of $3.53bn.
Where are Prestige Consumer Healthcare shares listed?
Here are the trading details for Prestige Consumer Healthcare:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: PBH
What kind of share is Prestige Consumer Healthcare?
Based on an overall assessment of its quality, value and momentum Prestige Consumer Healthcare is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Prestige Consumer Healthcare share price forecast for 2024?
The analyst consensus target price for shares in Prestige Consumer Healthcare is $82.40. That is 15.54% above the last closing price of $71.32.
Analysts covering Prestige Consumer Healthcare currently have a consensus Earnings Per Share (EPS) forecast of $4.42 for the next financial year.
Find out moreWhat is the trend in the Prestige Consumer Healthcare share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Prestige Consumer Healthcare. Over the past six months, its share price has underperformed the S&P500 Index by -10.18%.
As of the last closing price of $71.32, shares in Prestige Consumer Healthcare were trading +4.88% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Prestige Consumer Healthcare PE Ratio?
The Prestige Consumer Healthcare PE ratio based on its reported earnings over the past 12 months is 15.56. The shares last closed at $71.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Prestige Consumer Healthcare?
Prestige Consumer Healthcare's management team is headed by:
- Ronald Lombardi - CHM
- Christine Sacco - CFO
- Adel Mekhail - EVP
- William PPool - SVP
- Jeffrey Zerillo - SVP
- John Byom - IND
- Celeste Clark - IND
- Christopher Coughlin - IND
- Sheila Hopkins - IND
- Natale Ricciardi - IND
- Dawn Zier - IND